A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality

Thairu et al., Journal of Pharmaceutical Research International, doi:10.9734/jpri/2022/v34i44A36328 (date from preprint)

Feb 2022

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.00000000001 from 105 studies, recognized in 23 countries.

Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,100+ studies for 112 treatments. c19ivm.org

PSM retrospective 87 patients in Nigeria, 61 treated with ivermectin, showing lower mortality, faster recovery, and faster viral clearance with ivermectin treatment. All patients received zinc and vitamin C. A synergistic effect was seen for viral clearance when ivermectin and remdesivir were combined, as predicted by In Vitro research1. Subject to confounding by time, with ivermectin patients from April-June 2021, and non-ivermectin patients from September-November 2021.

This is the 79th of 105 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 774 quintillion).

52 studies are RCTs, which show efficacy with p=0.00000021.

This study is excluded in the after exclusion results of meta analysis: significant confounding by time possible due to separation of groups in different time periods.

Important missing comments or errors? Let us know.

risk of death, 87.9% lower, RR 0.12, p = 0.12, treatment 0 of 21 (0.0%), control 4 of 26 (15.4%), NNT 6.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), propensity score matching.

risk of death, 93.0% lower, RR 0.07, p = 0.007, treatment 0 of 61 (0.0%), control 4 of 26 (15.4%), NNT 6.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), all patients.

time to discharge, 54.6% lower, relative time 0.45, p < 0.001, treatment 61, control 26, propensity score matching.

risk of no viral clearance, 94.8% lower, RR 0.05, p = 0.001, treatment 0 of 21 (0.0%), control 10 of 26 (38.5%), NNT 2.6, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), propensity score matching, day 21.

risk of no viral clearance, 95.2% lower, RR 0.05, p < 0.001, treatment 1 of 21 (4.8%), control 26 of 26 (100.0%), NNT 1.1, propensity score matching, day 14.

risk of no viral clearance, 28.6% lower, RR 0.71, p = 0.005, treatment 15 of 21 (71.4%), control 26 of 26 (100.0%), NNT 3.5, propensity score matching, day 5.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Jeffreys et al., Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542.sciencedirect.com, doi.org.

Thairu et al., 25 Feb 2022, retrospective, Nigeria, peer-reviewed, mean age 41.7, 6 authors, study period April 2021 - November 2021, dosage 200μg/kg days 1-5. Contact: bablo57@gmail.com.

This Paper Ivermectin All

A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality

Y Thairu, O E Babalola, A A Ajayi, Y Ndanusa, J O Ogedengbe, Omede O.

Journal of Pharmaceutical Research International, doi:10.9734/jpri/2022/v34i44a36328

Aim: To compare outcomes from ivermectin (IVM) -and non-ivermectin (NIVM)-based treatments for COVID-19 in Abuja, Nigeria. Methods: Sixty-one consecutive virology-proven cases were recruited and managed with IVMbased regimes. A subsequent cohort of 26 patients was treated with NIVM due to physician preference, with varying combinations of lopinavir/ritonavir (Alluvia), remdesivir, azithromycin, and enoxapramin. All patients received zinc sulfate, vitamin C and supportive therapy. Propensity matching was carried out as indicated, and Repeat Measures Analysis of Variance (RMANOVA) allowing for time*treatment interaction was carried out for time dependent variables, deriving Likelihood Ratio (LR) and P values. Original Research Article Main Outcome Measures: Change in cycle threshold (viral load) over time, positivity status by day 5, improvement in clinical status using myalgia scores, days to discharge (DTD), change in SpO2 and death. Results: IVM was associated with a greater and faster reduction in viral clearance (LR=64.2 p< 0.0001 for the N gene): 31% and 95% were negative by days 5 and 14, respectively, versus 0% on NIVM. The mean DTD on IVM was 8.8 days versus 19.4 days, p< 0.0001. IVM proved significantly superior for Myalgia scores, LR= 23.45, P=0.0007. The mortality rate was 0/61 (0%) in IVM but 4/26 (15.3%) in NIVM. Three of the 4 deaths were in females, and 2 had been vaccinated, one fully. The SP02% increased significantly more on IVM (p < 0.0001 RMANOVA) than the NIVM group. C-reactive protein and D-dimer levels dropped significantly more sharply during IVM (P= 0.0068, 0.063), suggesting anti-inflammatory and antifibrinolytic activity. Conclusions: The IVM-based regimen caused earlier discharge from treatment and reduced mortality, in addition to clinical and laboratory improvements. Vaccination did not protect some patients from SARS-CoV-2 breakthrough infection and mortality.

ETHICS APPROVAL AND CONSENT The Project was approved by the University of Abja Teaching Hospital Human Research Ethics Committee. The Approval number was UATH/HREC/PR/2020/015/10. Consent to participate was obtained from each individual patient using a standard consent form in which the project was explained. COMPETING INTERESTS Authors have declared that no competing interests exist.

References

Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of Ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis

Arshad, Pertinez, Box, Prioritization of Anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics, Clin Pharmacol Ther, doi:10.1002/cpt.1909

Babalola, Bode, Ajayi, Alakaloko, Akase et al., A Randomized Controlled Trial of Ivermectin Monotherapy versus Hydroxychloroquine, Ivermectin, and Azithromycin Combination Therapy in COVID-19 Patients in Nigeria, J Infect Dis Epidemiol, doi:.org/10.23937/2474-3658/1510233

Bobrowski, Chen, Eastman, Synergistic and Antagonistic Drug Combinations against SARS-CoV-2, Mol Ther, doi:10.1016/j.ymthe.2020.12.016

Bryant, Lawrie, Dowswell, Fordham, Mitchell, Ivermectin for prevention and treatment of COVID-19 infection: A systematic review, metaanalysis, and trial sequential analysis to inform clinical guidelines, Am J Ther

Budhiraja, Soni, Jha, Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience, doi:10.1101/2020.11.16.20232223v1

Buonfrate, Chesini, Martini, High-dose Ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2021.106516

Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Research

Chahla, Ruiz, Mena, Cluster Randomised Trials -Ivermectin Repurposing For COVID-19 Treatment of Outpatients With Mild Disease In Primary Health Care Centers, doi:10.21203/rs.3.rs-495945/v1

Chandrima, Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India, Journal of Pharmacy and Pharmaceutical Sciences, doi:10.18433/jpps32105

Dinicolantonio, Barroso, Mccarty, Ivermectin may be a clinically useful antiinflammatory agent for late-stage COVID-19 [published correction appears, Open Heart

Elalfy, Besheer, El-Mesery, Effect of a combination of nitazoxanide, ribavirin, and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19, J Med Virol, doi:10.1002/jmv.26880

Hay, Arnott, Ivermectin and coagulation: an in vitro study, Ann Trop Med Parasitol

Kory, Gianfranco, Varon, Iglesias, Marik, Review of the emerging evidence demonstrating the efficacy of Ivermectin in the prophylaxis and treatment of COVID-19, Am J Ther

Lehrer, Rheinstein, Ivermectin Docks to the SARS-CoV-2 Spike Receptorbinding Domain Attached to ACE2, Vivo, doi:10.21873/invivo.12134

Mahmud, Rahman, Alam, Ivermectin in combination with doxycycline for treating COVID-19 symptoms: A randomized trial, Journal of International Medical Research, doi:10.1177/03000605211013550

Maiada, Hashem Clinicaltrials, None

Maragakis, Kelen, Breakthrough infections: Coronavirus after vaccination

Matsuyama, Kubli, Yoshinaga, An aberrant STAT pathway is central to COVID-19, Cell Death Differ, doi:10.1038/s41418-020-00633-7

Mohan, Tiwari, Suri, Singledose oral Ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial, J Infect Chemother, doi:10.1016/j.jiac.2021.08.021

Omura, Crump, Ivermectin: panacea for resource-poor communities?, Trends Parasitol, doi:10.1016/j.pt.2014.07.005

Rajter, Sherman, Fatteh, Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study), doi:10.1016/j.chest.2020.10.009

Ravi, Ranjini, Pattadar

Richards, Mcneeley, Bryan, Ivermectin and prothrombin time, The Lancet

Seth, Mas, Conod, Mueller, Siems et al., Long-Lasting WNT-TCF response blocking and epigenetic modifying activities of withanolide f in human cancer cells, PLoS One

Stone, Ndarukwa, Scheim, Rapid increase od SpO2 on room air for 34 severe COVID-19 patients after Ivermectin-based combination treatement, doi:10.21203/rs.3.rs-1048271/v1

Thakur, Bhola, Thakur, Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe, Infection, doi:10.1007/s15010-021-01734-2

Wagstaff, Ivermectin Global Summit

Whitworth, Hay, Mcnicholas, Morgan, Maude et al., Coagulation abnormalities and Ivermectin, Ann Trop Med Parasitol

Yan, Ci, Chen, Anti-Inflammatory effects of Ivermectin in mouse model of allergic asthma, Inflamm Res

Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral Ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antivir Res

Zhang, Song, Ci, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPSinduced survival in mice, Inflamm Res, doi:10.1007/s00011-008-8007-8

{ 'indexed': {'date-parts': [[2022, 9, 1]], 'date-time': '2022-09-01T04:55:38Z', 'timestamp': 1662008138842}, 'reference-count': 0, 'publisher': 'Sciencedomain International', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': 'Aim: To compare outcomes from ivermectin (IVM) - and non-ivermectin (NIVM)-based ' 'treatments for COVID-19 in Abuja, Nigeria.\n' 'Methods: Sixty-one consecutive virology-proven cases were recruited and managed with ' 'IVM-based regimes. A subsequent cohort of 26 patients was treated with NIVM due to physician ' 'preference, with varying combinations of lopinavir/ritonavir (Alluvia), remdesivir, ' 'azithromycin, and enoxapramin. All patients received zinc sulfate, vitamin C and supportive ' 'therapy. Propensity matching was carried out as indicated, and Repeat Measures Analysis of ' 'Variance (RMANOVA) allowing for time*treatment interaction was carried out for time dependent ' 'variables, deriving Likelihood Ratio (LR) and P values.\n' 'Main Outcome Measures: Change in cycle threshold (viral load) over time, positivity status by ' 'day 5, improvement in clinical status using myalgia scores, days to discharge (DTD), change ' 'in SpO2 and death.\n' 'Results: IVM was associated with a greater and faster reduction in viral clearance (LR=64.2 ' 'p< 0.0001 for the N gene): 31% and 95% were negative by days 5 and 14, respectively, ' 'versus 0% on NIVM. The mean DTD on IVM was 8.8 days versus 19.4 days, p< 0.0001. IVM ' 'proved significantly superior for Myalgia scores, LR= 23.45, P=0.0007. The mortality rate was ' '0/61 (0%) in IVM but 4/26 (15.3%) in NIVM. Three of the 4 deaths were in females, and 2 had ' 'been vaccinated, one fully. The SP02% increased significantly more on IVM (p < 0.0001 ' 'RMANOVA) than the NIVM group. C-reactive protein and D-dimer levels dropped significantly ' 'more sharply during IVM (P= 0.0068, 0.063), suggesting anti-inflammatory and antifibrinolytic ' 'activity.\n' 'Conclusions: The IVM-based regimen caused earlier discharge from treatment and reduced ' 'mortality, in addition to clinical and laboratory improvements. Vaccination did not protect ' 'some patients from SARS-CoV-2 breakthrough infection and mortality.', 'DOI': '10.9734/jpri/2022/v34i44a36328', 'type': 'journal-article', 'created': {'date-parts': [[2022, 7, 11]], 'date-time': '2022-07-11T04:33:25Z', 'timestamp': 1657514005000}, 'page': '1-19', 'source': 'Crossref', 'is-referenced-by-count': 2, 'title': 'A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on ' 'Virus Clearance, Days-to-discharge and Mortality', 'prefix': '10.9734', 'author': [ {'given': 'Y.', 'family': 'Thairu', 'sequence': 'first', 'affiliation': []}, {'given': 'O. E.', 'family': 'Babalola', 'sequence': 'first', 'affiliation': []}, {'given': 'A. A.', 'family': 'Ajayi', 'sequence': 'first', 'affiliation': []}, {'given': 'Y.', 'family': 'Ndanusa', 'sequence': 'first', 'affiliation': []}, {'given': 'J. O.', 'family': 'Ogedengbe', 'sequence': 'first', 'affiliation': []}, {'given': 'Omede', 'family': 'O.', 'sequence': 'first', 'affiliation': []}], 'member': '4694', 'published-online': {'date-parts': [[2022, 7, 8]]}, 'container-title': 'Journal of Pharmaceutical Research International', 'original-title': [], 'link': [ { 'URL': 'https://journaljpri.com/index.php/JPRI/article/download/36328/68696', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://journaljpri.com/index.php/JPRI/article/download/36328/68697', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://journaljpri.com/index.php/JPRI/article/download/36328/68696', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 7, 11]], 'date-time': '2022-07-11T04:33:25Z', 'timestamp': 1657514005000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journaljpri.com/index.php/JPRI/article/view/36328'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 7, 8]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.9734/jpri/2022/v34i44A36328', 'relation': {}, 'ISSN': ['2456-9119'], 'subject': ['General Medicine'], 'container-title-short': 'JPRI', 'published': {'date-parts': [[2022, 7, 8]]}}

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0